Methodological advances in the design and analysis of stroke trials

Abstract

Background:

Despite major advances in the prevention and treatment of stroke, many stroke trials have yielded neutral or modestly positive results due to multiple factors, including patient heterogeneity, small treatment effects, inadequate statistical efficiency, and in some settings limited biological efficacy or insufficient early-phase validation of interventions.

Summary of review:

This review summarizes emerging methodological innovations relevant to contemporary stroke trials, including group sequential methods, adaptive design (response-adaptive randomization, sample size re-estimation, enrichment strategies), Bayesian designs, and master protocol frameworks (basket, umbrella, and platform trials). We also discuss advances in outcome assessment, including hierarchical composite endpoints analyzed using the win ratio, ordinal and utility-weighted analyses of the modified Rankin Scale, and the growing role of patient-reported outcomes in capturing patient-centered benefits across the recovery continuum. Finally, we highlight stroke-specific methodological challenges and outline future opportunities enabled by advances in imaging, digital health, and data-driven approaches.

Conclusion:

Together, these innovations have the potential to improve the efficiency, interpretability, and clinical relevance of stroke trials, provided they are implemented within rigorously pre-specified protocols that preserve trial integrity and valid statistical inference.

Graphical abstract

Keywords

Clinical trial methodology stroke epidemiology intervention neurology

Get full access to this article

View all access options for this article.

References

Broderick

Palesch

Demchuk

, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368: 893–903.

Ciccone

Valvassori

Nichelatti

, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 904–913.

Harloff

Schlachetzki

Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 379: 986–987.

Hill

Goyal

Menon

, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 2020; 395: 878–887.

Johnston

Easton

Farrant

, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215–225.

Lees

Zivin

Ashwood

, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354: 588–600.

Shuaib

Lees

Lyden

, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562–571.

Wang

Zhao

, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

Donnan

Fisher

Macleod

, et al. Stroke. Lancet 2008; 371: 1612–1623.

10.

Lord

Gebski

Keech

AC.

Multiple analyses in clinical trials: sound science or data dredging?

Med J Aust 2004; 181: 452–454.

11.

Rothwell

PM.

Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176–186.

12.

van Klaveren

Varadhan

Kent

. The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement. Ann Intern Med 2020; 172: 776.

13.

Rudd

Bowen

Young

, et al. The latest national clinical guideline for stroke. Clin Med 2017; 17: 154–155.

14.

Slyter

Ethical challenges in stroke research. Stroke 1998; 29: 1725–1729.

15.

Kim

Appelbaum

Jeste

Olin

JT.

Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations. Am J Psychiatry 2004; 161: 797–806.

16.

Young

Lees

Weir

; Glycine Antagonist in Neuroprotection International Trial Steering Committee and Investigators. Strengthening acute stroke trials through optimal use of disability end points. Stroke 2003; 34: 2676–2680.

17.

Optimising Analysis of Stroke Trials (OAST) Collaboration; Bath

Gray

Collier

Pocock

Carpenter

. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007; 38: 1911–1915.

18.

Lees

Bath

Schellinger

, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 2012; 43: 1163–1170.

19.

Saver

JL.

Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke 2011; 42: 2356–2362.

20.

Ganesh

Luengo-Fernandez

Rothwell

PM.

Author response: ordinal vs dichotomous analyses of modified Rankin scale, 5-year outcome, and cost of stroke. Neurology 2019; 93: 725.

21.

Savitz

Lew

Bluhmki

Hacke

Fisher

Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007; 38: 3205–3212.

22.

Pocock

SJ.

Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 1982; 38: 153–162.

23.

Sébille

Bellissant

Sequential methods and group sequential designs for comparative clinical trials. Fundam Clin Pharmacol 2003; 17: 505–516.

24.

Jennison

Turnbull

Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman & Hall/CRC, 2000.

25.

National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.

26.

Campbell

Mitchell

Kleinig

, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372: 1009–1018.

27.

Zhang

Rosenberger

WF.

Response-adaptive randomization for clinical trials with continuous outcomes. Biometrics 2006; 62: 562–569.

28.

Robertson

Lee

López-Kolkovska

Villar

SS.

Response-adaptive randomization in clinical trials: from myths to practical considerations. Stat Sci 2023; 38: 185–208.

29.

King

Lawrence

Milling

Warach

SJ.

Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. Int J Stroke 2019; 14: 977–982.

30.

Wang

Chow

SC.

Sample size re-estimation in clinical trials. Stat Med 2021; 40: 6133–6149.

31.

Proschan

Hunsberger

SA.

Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–1324.

32.

McClure

Szychowski

Benavente

Coffey

CS.

Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience. Contemp Clin Trials 2012; 33: 1088–1093.

33.

Campbell

BCV

Schwamm

, et al. Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design. Stroke Vasc Neurol 2022; 7: 71–76.

34.

Park

Liu

Thall

Yuan

Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics 2022; 78: 60–71.

35.

Lee

Liu

DD.

A predictive probability design for phase II cancer clinical trials. Clin Trials 2008; 5: 93–106.

36.

Nogueira

Jadhav

Haussen

, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378: 11–21.

37.

Albers

Marks

Kemp

, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378: 708–718.

38.

Berry

DA.

Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27–36.

39.

Spiegelhalter

Freedman

Parmar

MKB

. Bayesian approaches to randomized trials. J R Stat Soc Ser A Stat Soc 2018; 157: 357–387.

40.

Pradilla

Ratcliff

Hall

, et al. Trial of early minimally invasive removal of intracerebral hemorrhage. N Engl J Med 2024; 390: 1277–1289.

41.

Cunanan

Iasonos

Shen

, et al. An efficient basket trial design. Stat Med 2017; 36: 1568–1579.

42.

Thall

Wathen

Bekele

, et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 2003; 22: 763–780.

43.

Ren

Chen

Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial. Contemp Clin Trials 2021; 109: 106538.

44.

Pitre

Cheng

Cusano

, et al. Methodology and design of platform trials: a meta-epidemiological study. J Clin Epidemiol 2023; 157: 1–12.

45.

Greenstreet

Jaki

Bedding

, et al. A multi-arm multi-stage platform design that allows preplanned addition of arms while still controlling the family-wise error. Stat Med 2024; 43: 3613–3632.

46.

van der Steen

van de Graaf

Chalos

, et al. Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. Lancet 2022; 399: 1059–1069.

47.

Pocock

Ariti

Collier

Wang

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33: 176–182.

48.

Redfors

Gregson

Crowley

, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J 2020; 41: 4391–4399.

49.

Gregson

Donners

SJA

Dippel

, et al. Use of the win ratio for analysis of stroke trials: description, illustration, and planned use in the second European Carotid Surgery Trial (ECST-2). Stroke 2025; 56: 230–238.

50.

Berkhemer

Fransen

Beumer

, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11–20.

51.

Goyal

Demchuk

Menon

, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372: 1019–1030.

52.

Price-Haywood

Harden-Barrios

Carr

Reddy

Bazzano

van Driel

ML.

Patient-reported outcomes in stroke clinical trials 2002-2016: a systematic review. Qual Life Res 2019; 28: 1119–1128.

53.

Schmidt

Geisler

Urban

, et al. Stroke survivors’ preferences on assessing patient-reported outcome measures. J Patient Rep Outcomes 2023; 7: 124.

54.

Aked

Delavaran

Wennerström

Lindgren

AG.

Recovery, functional status, and health-related quality of life status up to 4 years after first-ever stroke onset: a population-based study. Neuroepidemiology 2024; 58: 481–491.

55.

Richardson

Campbell

Allen

Meyer

Teasell

The stroke impact scale: performance as a quality of life measure in a community-based stroke rehabilitation setting. Disabil Rehabil 2016; 38: 1425–1430.

56.

Linder

Rosenfeldt

Reiss

, et al. The home stroke rehabilitation and monitoring system trial: a randomized controlled trial. Int J Stroke 2013; 8: 46–53.

57.

Thomalla

Fiehler

Subtil

, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial. Lancet Neurol 2024; 23: 883–892.

58.

Deb-Chatterji

Pinho

Flottmann

, et al. Health-related quality of life after thrombectomy in young-onset versus older stroke patients: a multicenter analysis. J Neurointerv Surg 2022; 14: 1145–1150.

59.

Jones

Mulder

Wruck

, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021; 384: 1981–1990.